LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Stock List・Innoviva Inc

Innoviva Inc

Closed

SectorHealthcare

22.45 1.35

Buy Sell

Overview

Share price change

24h

Current

Min

21.96

Max

22.49

Key metrics
By Trading Economics
Income	-55M 187M
Sales	-20M 98M
P/E Sector Avg	3.482 49.701
EPS	0.468
Profit margin	190.415
Employees	159
EBITDA	-160M 48M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+54.05% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-93M 1.6B
Previous open	21.1
Previous close	22.45

News Sentiment

By Acuity

19%

81%

27 / 345 Healthcare

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 May 2026, 16:33 UTC

Earnings

Major Market Movers

Webull Shares Slide on 1Q Loss, Soaring Costs

22 May 2026, 21:10 UTC

Earnings

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 May 2026, 19:47 UTC

Earnings

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 May 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 May 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 May 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 May 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 May 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 May 2026, 18:35 UTC

Acquisitions, Mergers, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 May 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 May 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 May 2026, 17:54 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

22 May 2026, 17:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 May 2026, 17:54 UTC

Market Talk

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 May 2026, 17:03 UTC

Market Talk

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 May 2026, 16:54 UTC

Market Talk

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 May 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 May 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 May 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

22 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 May 2026, 16:16 UTC

Market Talk

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 May 2026, 15:55 UTC

Market Talk

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 May 2026, 15:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 May 2026, 15:42 UTC

Market Talk

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 May 2026, 15:35 UTC

Market Talk

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

54.05% upside

12 Months Forecast

Average 34.6 USD 54.05%

High 46 USD

Low 18 USD

Based on 5 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Innoviva Inc - Dist in the past 3 months.

Sentiment

By Acuity

27 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.